Amicus brief of over 300 reproductive health researchers supports mifepristone's safety and effectiveness
Bibliographic Data
| ID | 12775766 |
|---|---|
| Authors | Amanda Barrow, Cathren Cohen, Jaclyn Serpico (0000-0002-6406-7429), M David Goodman, Daniel Grossman (0000-0002-6878-6201, corresponding author), Sarah Raifman (0000-0002-5025-2412), Ushma D Upadhyay (0000-0002-2731-2157) |
| Year | 2024 |
| Volume | 56 |
| Issue | 4 |
| Pages | 317-319 |
| Publication date | 2024-07-29 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Perspectives on Sexual and Reproductive Health (JOURNAL) |
| Journal identifiers | ISSN: 1538-6341 • E-ISSN: 1931-2393 |
| Publisher | Wiley (PUBLISHER • GB) |
| DOI | 10.1111/psrh.12282 |
| PMID | 39074978 |
| OpenAlex | W4401155737 |
| Language | EN |
| References cited | 5 |
On January 30, 2024, over 300 researchers filed an amicus brief in FDA v. Alliance for Hippocratic Medicine, a United States (US) Supreme Court case concerning the regulatory status of mifepristone, one of two drugs used in medication abortion. In this Comment we summarize the legal challenge, responses from the FDA and drug manufacturer to these challenges, oral arguments presented before the Court, and the implications of the Court's decision on access to mifepristone in the US. We also summarize the content of the accompanying amicus brief
Abortion · Alliance · Alternative medicine · Emergency contraception · Environmental health · Family medicine · Family planning · Mifepristone · Misoprostol · Political science · Population · Pregnancy · Research methodology · Supreme court · Supreme Court Decisions · Law · Medicine · Pregnancy and Medication Impact · Reproductive Health and Contraception · Reproductive Health and Technologies
| Highly cited | No |
|---|